Clinical Trial Update: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment [Phase 2]

View source ↗

Summary

This Phase 2 trial update shows the study of RO5024048 in combination with ritonavir-boosted danoprevir and Pegasys/Copegus in chronic hepatitis C genotype 1 pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• RO5024048
• Ritonavir-boosted danoprevir (danoprevir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: WITHDRAWN